Trade Revolution Medicines, Inc. - RVMD CFD
Add to favourite- Summary
- Historical Data
Spread | 0.10 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 39.11 |
Open | 39.27 |
1-Year Change | 68.54% |
Day's Range | 39.11 - 40.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 3, 2024 | 40.14 | 0.38 | 0.96% | 39.76 | 40.16 | 39.04 |
May 2, 2024 | 39.11 | 0.15 | 0.39% | 38.96 | 39.55 | 38.16 |
May 1, 2024 | 38.75 | 1.64 | 4.42% | 37.11 | 39.41 | 36.98 |
Apr 30, 2024 | 37.22 | 0.70 | 1.92% | 36.52 | 37.63 | 36.46 |
Apr 29, 2024 | 37.02 | 0.96 | 2.66% | 36.06 | 37.16 | 36.06 |
Apr 26, 2024 | 35.88 | 0.72 | 2.05% | 35.16 | 36.28 | 34.48 |
Apr 25, 2024 | 35.30 | 0.48 | 1.38% | 34.82 | 35.76 | 34.48 |
Apr 24, 2024 | 35.51 | -0.72 | -1.99% | 36.23 | 36.24 | 35.21 |
Apr 23, 2024 | 36.20 | -0.16 | -0.44% | 36.36 | 37.75 | 35.96 |
Apr 22, 2024 | 36.36 | 1.19 | 3.38% | 35.17 | 36.65 | 34.74 |
Apr 19, 2024 | 34.87 | -0.95 | -2.65% | 35.82 | 36.30 | 34.17 |
Apr 18, 2024 | 35.78 | -0.77 | -2.11% | 36.55 | 37.10 | 35.68 |
Apr 17, 2024 | 36.74 | 0.51 | 1.41% | 36.23 | 37.47 | 36.00 |
Apr 16, 2024 | 36.20 | 1.21 | 3.46% | 34.99 | 36.56 | 34.99 |
Apr 15, 2024 | 35.50 | 0.00 | 0.00% | 35.50 | 36.31 | 34.55 |
Apr 12, 2024 | 36.00 | -1.47 | -3.92% | 37.47 | 37.79 | 35.17 |
Apr 11, 2024 | 37.34 | 0.78 | 2.13% | 36.56 | 38.67 | 35.56 |
Apr 10, 2024 | 36.41 | 2.71 | 8.04% | 33.70 | 37.43 | 33.53 |
Apr 9, 2024 | 32.95 | 0.95 | 2.97% | 32.00 | 33.39 | 31.79 |
Apr 8, 2024 | 31.86 | 0.49 | 1.56% | 31.37 | 31.95 | 30.94 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Revolution Medicines, Inc. Company profile
About Revolution Medicines Inc
Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Revolution Medicines Inc revenues decreased 32% to $29.4M. Net loss applicable to common stockholders increased 70% to $187.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 37% to $175.1M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
700 Saginaw Dr
REDWOOD CITY
CALIFORNIA 94063-4752
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com